# Potassium-Competitive Acid Blocker Versus pROton-Pump Inhibitor for GastroproTECTion Strategies In Patients at High Gastro-Intestinal Bleeding Risk Receiving Antithrombotic Therapy

Study · id `cardio:ct-nct04416581` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04416581](<https://clinicaltrials.gov/study/NCT04416581>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04416581

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease; Acute care and long-term living  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 3320 participants.

## Technical summary

Registry record NCT04416581. Randomized; quadruple masking; primary purpose prevention. Start 2021-05-12 (actual); primary completion 2027-12-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose prevention
- Phase: Phase 4
- Enrolled: 3320 participants (planned count; ClinicalTrials.gov record NCT04416581, source copy `cardio:ctgov-nct04416581-2026-08-28`, retrieved 2026-10-26)
- Started: 2021-05-12 (actual) (ClinicalTrials.gov record NCT04416581, source copy `cardio:ctgov-nct04416581-2026-08-28`, retrieved 2026-10-26)
- Primary completion: 2027-12-31 (anticipated) (ClinicalTrials.gov record NCT04416581, source copy `cardio:ctgov-nct04416581-2026-08-28`, retrieved 2026-10-26)
- Completion: 2028-02-28 (anticipated) (ClinicalTrials.gov record NCT04416581, source copy `cardio:ctgov-nct04416581-2026-08-28`, retrieved 2026-10-26)
- Countries: South Korea (ClinicalTrials.gov record NCT04416581, source copy `cardio:ctgov-nct04416581-2026-08-28`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04416581-2026-08-28`, retrieved 2026-10-26)

## The registry's words

- Brief title: Potassium-Competitive Acid Blocker Versus pROton-Pump Inhibitor for GastroproTECTion Strategies In Patients at High Gastro-Intestinal Bleeding Risk Receiving Antithrombotic Therapy
- Acronym: PROTECT-HBR
- Condition: Coronary Artery Disease
- Condition: Percutaneous Coronary Intervention
- Condition: Acute Coronary Syndrome
- Condition: Myocardial Infarction
- Intervention (Drug): PPI
- Intervention (Drug): P-CAB 50
- Lead sponsor: Duk-Woo Park, MD
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Acute coronary syndrome (`cardio:acute-coronary-syndrome`)
- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)
- Registry condition terms include this condition: Heart attack (myocardial infarction) (`cardio:myocardial-infarction`)
- Registry lists this organization as the lead sponsor: Duk-Woo Park, MD (`cardio:org-duk-woo-park-md`)

## Provenance

Content hash: 87e2d0f0e9757265289c92a2b1041277a96bd3eeff63792c054b0530dc020fe9
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
